Scientific Presentations

2023

Phase 1/2 Trial of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Patients with Thyroid Eye Disease (TED)
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023

VRDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic/Pharmacodynamic (PK/PD) Results in Healthy Volunteers
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023

 

Preclinical Pharmacokinetics and Bioavailability of VRDN-002, a Next-Generation Half-Life Extended Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED)
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023

Preclinical Pharmacokinetics of VRDN-003, a Next-Generation Half-life Extended Antibody to the IGF-1 Receptor for Thyroid Eye Disease
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023

Design and Preclinical Characterization of VRDN-003, a Next Generation, Half-life Extended Antibody to IGF-1R in Development for Thyroid Eye Disease (TED)
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023

VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Phase 1/2 Clinical Study in Patients

North American Neuro-Ophthalmology Society 2023 Annual Meeting

March 2023

THRIVE Phase 3 Trial of VRDN-001: A Full Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED)

North American Neuro-Ophthalmology Society 2023 Annual Meeting

March 2023

VRDN-001, a Full Antagonist Antibody to IGF-1R in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab

North American Neuro-Ophthalmology Society 2023 Annual Meeting

March 2023

VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED): Interim Phase 1/2 Pharmacodynamic Results

North American Neuro-Ophthalmology Society 2023 Annual Meeting

March 2023

VRDN-002, a Novel Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Results of a Phase 1 Trial

North American Neuro-Ophthalmology Society 2023 Annual Meeting

March 2023

2022

VRDN-001, A Potent and Selective Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease (TED): Phase 1 Safety and Pharmacodynamic Results in Healthy Volunteers

American Thyroid Association (ATA) 2022 Annual Meeting

October 22, 2022

VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) for Thyroid Eye Disease (TED): Phase 1/2 Proof of Concept in Patients with TED

American Thyroid Association (ATA) 2022 Annual Meeting

October 21, 2022

VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab

American Thyroid Association (ATA) 2022 Annual Meeting

October 20, 2022

2021

Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody for the Treatment of Thyroid Eye Disease

American Thyroid Association (ATA) 2021 Annual Meeting

October 2, 2021

VRDN-002, A Second-Generation Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody for TED: Preclinical PK Profile and Clinical Promise

American Thyroid Association (ATA) 2021 Annual Meeting

September 30, 2021